Brainstorm Cell Therapeutics Management
Management criteria checks 1/4
Brainstorm Cell Therapeutics' CEO is Chaim Lebovits, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $1.13M, comprised of 39.1% salary and 60.9% bonuses, including company stock and options. directly owns 1.52% of the company’s shares, worth $108.58K. The average tenure of the management team and the board of directors is 1.8 years and 6.7 years respectively.
Key information
Chaim Lebovits
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 39.1% |
| CEO tenure | 1.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 1.8yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
May 30Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02BrainStorm Cell Therapeutics EPS beats by $0.07
Apr 26Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
BrainStorm Cell Therapeutics EPS misses by $0.18
Feb 04Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17BrainStorm completes dosing in Phase 2 MS Study
Dec 18BrainStorm launches NurOwn Expanded Access Program
Dec 14What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13BrainStorm's NurOwn flunks in late-stage ALS study
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$442k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$17m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$500k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$1m | US$500k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$500k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$29m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$1m | US$500k | -US$23m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$2m | US$500k | -US$14m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$5m |
| Dec 31 2017 | US$1m | US$391k | -US$5m |
Compensation vs Market: Chaim's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD649.63K).
Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.
CEO
Chaim Lebovits (53 yo)
1.8yrs
Tenure
US$1,128,795
Compensation
Mr. Chaim Lebovits is President & Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from January 2023. Mr. Lebovits was Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from April 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 1.8yrs | US$1.13m | 1.52% $ 108.6k | |
| Co-Founder & Independent Vice Chair of the Board | 20.5yrs | no data | 0.20% $ 13.9k | |
| Interim CFO & Controller | 11.9yrs | US$146.78k | 0.082% $ 5.8k | |
| Executive VP | 7.7yrs | US$247.06k | 0.16% $ 11.4k | |
| Executive VP & COO | less than a year | no data | no data | |
| Chief Scientific Advisor | no data | no data | no data | |
| Senior Vice President of Patient Advocacy & Government Affairs | 2.8yrs | no data | no data | |
| Executive VP & Chief Medical Officer | 1.3yrs | no data | 0.24% $ 17.0k | |
| Senior Vice President of Research and Development | less than a year | no data | no data |
1.8yrs
Average Tenure
54yo
Average Age
Experienced Management: BCLI's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Independent Vice Chair of the Board | 20.5yrs | no data | 0.20% $ 13.9k | |
| Executive VP | 10.4yrs | US$247.06k | 0.16% $ 11.4k | |
| Independent Chairman of the Board | 4.7yrs | no data | 0.071% $ 5.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Business Advisory Board | 13.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Business Advisory Board | 17.1yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 6.7yrs | no data | no data | |
| Independent Director | 6.8yrs | US$12.50k | 0.033% $ 2.3k | |
| Member of Scientific Advisory Board | 1.8yrs | US$4.46m | no data | |
| Director | less than a year | US$1.01m | 0.45% $ 32.4k | |
| Independent Director | 1.4yrs | no data | no data |
6.7yrs
Average Tenure
64yo
Average Age
Experienced Board: BCLI's board of directors are considered experienced (6.7 years average tenure).